Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Hang Quach; Liam Fernyhough; Ross Henderson; Gillian Corbett; Bart Baker; Peter Browett; Hilary Blacklock; Cecily Forsyth; Craig Underhill; Paul Cannell; Judith Trotman; Annette Neylon; Simon Harrison; Emma Link; Arlene Swern; Linda Cowan; Meletios A. Dimopoulos; H. Miles Prince
Author Information: Faculty of Medicine
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.